期刊文献+

安今益的基础研究与临床功用

Base study and Clinical effect of Angeliq
下载PDF
导出
摘要 绝经后妇女由于卵巢功能衰退,性激素水平的明显改变,可能发生躯体、精神、心理等方面的症状,出现潮热、失眠、易怒等更年期症状且患骨质疏松、心血管疾病等疾病的概率也会大大增加。因此地合理地激素补充治疗至关重要。安今益(Angeliq)含低剂量的天然雌激素及对控制血压和体重有利的孕激素-屈螺酮(Drospirenone,DRSP),可以使妇女在改善更年期症状的同时,降低心血管病的风险,有更多的受益。本文将对安今益的基础研究以及临床功用进行综述。 Postmenopausal women suffered from menopausal symptoms, come from the body, consciousness and psychology like hot flushes, insomnia and irascibility due to the level of hermones had changed obviously because of declining of overy funetion during menopause. Furthermore the probability of osteoporosis and cardiovascular disease had greatly increased. Thus hormone replacement therapy reasonably is more important. Angeliq, combination with low-dose nature estrogen and progestin-drospirenone ,that showed benefit to control blood pressure and weight, may improve the menopausal symptoms and reduce the risk of cardiovascular disease,that' s the potential additional benefit.
作者 徐伯兰
出处 《武警医学院学报》 CAS 2012年第6期484-488,共5页 Acta Academiae Medicinae CPAPF
关键词 安今益 绝经期 激素补充治疗 更年期症状 Angeliq Menopause Hormone Replacement therapy Menopausal symptoms
  • 相关文献

参考文献29

  • 1Oelkers W. Drospirenone, a progestogen with auti-minera- locorticoid properties: a short review[J]. Mol Cell Endorinol, 2004, 217(12):255-261.
  • 2Apter D, Borsos A, Baumgartner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms[J]. Eur J Contracept Reprod Health Care, 2003, 8(1):37-51.
  • 3Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone[J]. Climacteric, 2005, 8(3):4-12.
  • 4Oelkers W. Drospirenone: antimineralocorticoid activity, progestogen with resembling natural progeste- rone[J]. Eur J Contracept Reprod health Care, 2000, 5(3): 17-24.
  • 5Parsey KS, Pong A. An open-labe, muhicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen[J]. Contracep- tion, 2000, 61(2):105-111.
  • 6Krattenmacher R. Drospirenone pharmacology and pharm- acokinetics of a unique progestogen[J]. Contraception, 2000,62(2):29-38.
  • 7Rubig A. Drospirenone: a new cardiovascular-active prog- estin with Anti-aldosterone and anti-androgenic properties [J]. Climacteric, 2003, 6(3):49-54.
  • 8Lin SQ, Sun LZ, Lin JF, et al. Estradiol 1 mg and dros- pirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women[J]. Climacteric, 2011, 14(4): 472-481.
  • 9周远征,孙丽洲,林金芳,杨欣,张莉嘉,乔杰,王泽华,许燕雪,熊正爱,林守清.雌二醇屈螺酮片治疗绝经后妇女绝经相关症状的多中心临床研究[J].中华妇产科杂志,2011,46(5):345-349. 被引量:11
  • 10Foidart JM. Added benefits of drospirenone for compliance [J]. Climacteric, 2005, 8(3):28-34.

二级参考文献9

  • 1林守清.女性围绝经期激素治疗国内外近期临床应用进展[J].中国实用妇科与产科杂志,2006,22(1):23-25. 被引量:20
  • 2王绍海,林守清,桂启芳,金敏娟,姜颖.低剂量性激素治疗及中药治疗引起的非计划性阴道出血[J].中国医学科学院学报,2006,28(2):256-261. 被引量:17
  • 3Archer DF,Thomeycroft IH,Foegh M,et al.Long-term safety of drospirenone-estradiol for hormone therapy:a randomized,double-blind,muhicenter trial.Menopause,2005,12:716-727.
  • 4Warren MP,Halpert S.Hormone replacement therapy:controversies,pros and cons.Best Pract Res Clin Endecrinol Metab,2004,18:317-332.
  • 5Rossi R,Grimaldi T,Origliani G,et al.Menopause and cardiovascular risk.Pathophysiol Haemost Thromb,2002,32:325-328.
  • 6Lund KJ.Menopause and the menopausal transition.Med Clin North Am,2008,92:1253-1271.
  • 7North American Menopause Society.Estrogen and progestogen use in postmenopausal women:2010 position statement of The North American Menopause Society.Menopause,2010,17:242-255.
  • 8Collins JA,Blake JM,Crosignani PG.Breast cancer risk with postmenopausal hormonal treatment.Hum Reprod Update,2005,11:545-560.
  • 9Otto C,Fuehs I,Altmann H,et al.Comparative analysis of the uterine and mammary gland effects of drespirenone and medroxyprogesterone acetate.Endocrinology,2008,149:3952-3959.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部